Survey to Specify SGLT2 Inhibitor Choice in T2DM Management

OBJECTIVE: There are no major head-to-head comparative studies till date to compare the differences in glycemic efficacy, safety, or cardio-renal effects within SGLT2 inhibitors. This survey was conducted to understand the different parameters that clinicians identify while choosing an SGLT2 inhibit...

全面介紹

書目詳細資料

Principais autores:	Samit Ghosal, Radhika M. Joshi, Rahul N. Iyer, Samir M. Adsule
格式:	Artigo
語言:	Inglês
出版:	Via Medica 2022-10-01
叢編:	Clinical Diabetology
主題:	SGLT2 inhibitors canagliflozin empagliflozin survey T2DM CVD
在線閱讀:	https://journals.viamedica.pl/clinical_diabetology/article/view/87411
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!